AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05198531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 Injection
Description: TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.
Study NCT05198531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study NCT05198531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride injection
Description: Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.
Study NCT05198531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection
Description: After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
Study NCT06076772 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors
Study NCT06263660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Keto-like supplement
Description: Participants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.
Study NCT06263660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.
Study NCT04841694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bacillus indicus
Study NCT06044129 — intervention group
Intervention type: DEVICE
Intervention: Mri scan of fetal head and pelvis
Description: The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.
Study NCT06527209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coffee and agave inulin-based beverage (A)
Description: Intervention beverage:~134 mL of cold-brew coffee 18 g of agave inulin Total beverage weight: 350 g
Study NCT06527209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control beverage (B)
Description: Control beverage:~40 mL of cold brew coffee 5.4 g of agave inulin Total beverage weight: 350 g.
Study NCT05306184 — intervention group
Intervention type: PROCEDURE
Intervention: Electroconvulsive therapy (ECT)
Description: ECT
Study NCT04853992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020
Description: LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
Study NCT04853992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 placebo
Description: LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.
Study NCT05695677 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capacitive-Resistive Radiofrequency therapy of the neck muscles
Description: Capacitive-Resistive Radiofrequency therapy of the neck muscles as a non-invasive technique for treating PDPH.
Study NCT05916261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen tumor vaccine
Description: neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
Study NCT04503395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESAR treatment: Endograft + Heli-FX Endoanchor
Description: ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
Study NCT04503395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FEVAR treatment : Fenestrated endograft
Description: Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
Study NCT03327636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
Study NCT05073172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calendula Ointment
Description: Applied topically
Study NCT05073172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment
Description: Applied topically
Study NCT05073172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol Hydrogel
Description: Applied topically
Study NCT05073172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silicone-based Film Forming Topical Gel
Description: Applied topically
Study NCT05073172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine
Description: Applied topically
Study NCT05073172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Hydrocortisone
Description: Applied topically
Study NCT05610657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Mitapivat tablets
Study NCT06345586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone
Description: 4 mg tablet once daily
Study NCT04163055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moleculight i:X
Description: This device is used to visualize the bacteria in the wound. Patients do not need consume any contrast agent prior to imaging. The device does not come in contact with the wound.
Study NCT05315141 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT05686083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C6 ketone di-ester
Description: C6 ketone di-ester
Study NCT05686083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Novel ketone di-ester
Description: Novel ketone di-ester
Study NCT05438251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fespixon Cream
Description: 1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks
Study NCT05346770 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral Intervention
Description: A behavioral intervention could include changing the time of day a drug is taken.
Study NCT05346770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: A patient may receive a pharmacogenomic test via cheek swab to find PGx results. This is a benign intervention with little to no risk to the patient.
Study NCT05346770 — intervention group
Intervention type: OTHER
Intervention: Data Analysis
Description: Medication safety reviews, and retrospective or prospective data analysis may occur as a result of participation in a case study.
Study NCT06300931 — intervention group
Intervention type: OTHER
Intervention: educational lecture
Description: An Educational lecture about SDF
Study NCT06557798 — intervention group
Intervention type: DEVICE
Intervention: Any commercially available transcatheter aortic valve
Description: Redo TAVI will be performed using any commercially available transcatheter aortic valve according to the preferences of the local team in keeping with standard clinical care.
Study NCT06426446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings Body Comp Pro
Description: Withings Body Comp Pro from which the following features will be used: body weight, body composition (fat, muscle and bone mass, cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), nervous health (electrochemical skin conductance)
Study NCT05050006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITIL-168
Description: ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
Study NCT05067621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
Study NCT05067621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection pen contains excipients.
Study NCT04856826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guidance and therapeutic communication
Description: insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
Study NCT06557798 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical explantation and aortic valve replacement
Description: Surgical explantation and aortic valve replacement will be performed according to the preferences of the local team in keeping with standard clinical care. Any commercially available approved surgical aortic valve may be used. Additional surgery, such as aortic root replacement, root enlargement, CABG, mitral valve repair/replacement, etc. will be performed at the discretion of the local team.
Study NCT06557798 — intervention group
Intervention type: OTHER
Intervention: Conservative management
Description: Conservative treatment, including optimal medical therapy +/- balloon aortic valvuloplasty
Study NCT04571879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Lidocaine
Description: Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
Study NCT04571879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Midazolam
Description: Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
Study NCT04571879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized normal saline and intranasal normal sline
Study NCT04173559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Intervention
Description: After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
Study NCT05075486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative quality improvement
Description: Hospitals will receive standardized center-specific ECLS data report with benchmarking to feedback on their performance. Evidence-based potential better practice list will be established as a reference for all hospitals. During the intervention period, the hospitals will receive training in collaborative quality improvement method and then develop, implement, and document evidence-based practice changes to reduce adverse outcomes of neonatal ECLS treatment. Compliance with practice changes and neonatal outcomes will be monitored. All hospitals will have access to implementation support and collaborative activities.
Study NCT04702984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LID021201 contact lenses
Description: Investigational silicone hydrogel sphere contact lenses for frequent replacement daily wear
Study NCT04702984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE multipurpose solution
Description: Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
Study NCT05533762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arch insole and sham insole
Description: children wear insoles on feet
Study NCT05533762 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: arch insole and sham insole
Description: children wear insoles on feet
Study NCT05496335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: Intramuscular Injection
Study NCT05496335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection
Study NCT05496335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular Injection
Study NCT05394506 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin Biopsy
Description: The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
Study NCT05394506 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle biopsy
Description: The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
Study NCT06183151 — intervention group
Intervention type: DEVICE
Intervention: Entia Liberty System
Description: See arm/group description
Study NCT04766320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes.
Study NCT03633955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT
Description: F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
Study NCT05885048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for analysis
Description: Test hormone levels in blood
Study NCT03633955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLT
Description: F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
Study NCT05885048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sperm samples for analysis
Description: Spermiogram
Study NCT05885048 — intervention group
Intervention type: OTHER
Intervention: Satisfaction evaluation
Description: Participant satisfaction assessment
Study NCT04954300 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study NCT05885048 — intervention group
Intervention type: OTHER
Intervention: Quality of Life questionnaire
Description: The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)
Study NCT00758940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof ReSTOR multifocal IOL
Description: Implanted into the study eye following cataract extraction surgery
Study NCT03482986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary habits plan
Description: Patients will be given a personalized plan regarding their diet.
Study NCT05651763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation and exercise group
Description: Exercise protocol + application of active direct current stimulation for 30 minutes.
Study NCT05651763 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise and sham stimulation group
Description: Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
Study NCT06431191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral raw
Description: lateral raw repair for full tear rotator cuff combined microfracture procedure, without medial raw
Study NCT06431191 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: double raw
Description: double raw repair for full tear rotator cuff combined microfracture procedure
Study NCT05515406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7018
Description: ONO-7018 tablet(s) are administered orally
Study NCT05050292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized cognitive stimulation
Description: Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity.
Study NCT05050292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham cognitive stimulation
Description: Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game.
Study NCT03560583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 10 mg BID
Study NCT03560583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo 10 mg BID
Study NCT06387069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-306 Regimen
Description: Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.
Study NCT06387069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Chemotherapy Regimen
Description: Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:~* MEC regimen: etoposide injection 100 mg/m2, cytarabine injection 1000 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).~* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).~* LoDAC: cytarabine injection 20 mg q12h SC or IV for 10 consecutive days (Days 1-10).~* Azacitidine: azacitidine injection 75 mg/m2 QD SC or IV for 7 consecutive days (Days 1-7).
Study NCT06319209 — intervention group
Intervention type: OTHER
Intervention: Preoperative resolved COVID-19
Description: We observed postoperative outcomes only in patients who had or did not have COVID-19 before surgery, without any additional intervention.
Study NCT04813978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
Study NCT05006339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Monitoring
Description: Patients in this arm are not required to attend in-office retention appointments except if they have any problems with their retainers and when data collection is necessary. Instead they are required to submit scans of their teeth through the DM mobile application at the designated intervals.
Study NCT05006339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Review
Description: Patients in this arm are required to attend in clinic appointments for their retention review
Study NCT04971798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-free Stem Cell-derived Extract Formulation (CCM)
Description: Intraarticular injection
Study NCT06253026 — intervention group
Intervention type: OTHER
Intervention: Search and rescue mission
Description: Air search and rescue missions lasting 15 consecutive days
Study NCT04705311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.